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in pre-mobilization WBC counts and serum LDH levels.
However, the ratio of the LDH level immediately before
apheresis to the lowest one (“LDH-ratio”) were signiﬁcantly
lower in poor mobilizers than good mobilizers. Our ROC
analysis showed that the cut-off value of “LDH-ratio”was 1.75.
An elevation of serum LDH levels to reach “LDH-ratio”>1.75
were found to be a useful predictive factor for successful
CD34+ stem cell collection. The delay in reaching “LDH-
ratio”>1.75 may suggest that we should modify the mobili-
zation regimen by, for instance, adding prelixafor.Table 1
Pts’ characteristics
No. of Patients 55
Median age (range) 56(35-69)
Gender, male (%) 31(56)
Primary Disease
MM 19
NHL 26
HL 4
Others 6
Median WBC counts 103/mL (range) 2.1(1.5-3.2)
Median LDH Level IU/L (range) 196(145-445)
PBSC mobilization regimen
ESHAP 27
HD-CY 22
G-CSF alone 0
Others 6
MM indicates: multiple myeloma, NHL: non-hodgkin lymphoma, HL:
hodgkin lymphoma, HD-CY: high dose cyclophosphamide142
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Background: An HCT-CI score of 3 demonstrated signiﬁcant
differences in non-relapse mortality (NRM) and overall
survival independent from Karnofsky Performance Status
(KPS) in allogeneic HCT recipients. An HCT-CI score of 3 did
not predict NRM and survival in multiple myeloma (MM),
Hodgkin's Lymphoma (HL) and non-Hodgkin's Lymphoma
(NHL), but did predict signiﬁcant differences in the devel-
opment of grade 3-5 toxicities in NHL patients.
Purpose: Use of HCT-CI score to predict grade 3-5 toxicities
within 90 days post-autologous HCT in elderly patients.
Method: RetrospectivelyutilizedanHCT-CI scoreof3 topredict
grade 3-5 toxicities in autologous HCT patients  65 years in
a single HCT center in 2011. Outcome variables included
pulmonary (pneumonitisorﬁbrosis), gastrointestinal (diarrhea,
nausea ormucositis), neurologic (confusion), renal dysfunction
(increased creatinine), hepatic dysfunction (increased ALT/
AST), cardiovascular (decreased ejection fraction, and atrial or
ventricular arrythmias), fatigue and bone pain. Grading criteria
were based on the National Cancer Institute Common Termi-
nology Criteria Adverse Events version 4.0.
Results: The sample consisted of 37 autologous HCT recipi-
ents a mean of 67.4 years (range of 65-71), including 19
males (51.4%) and 18 females (48.6%) with the following
diagnoses MM (13), HL (1) NHL (21) and amyloidosis (2). Atthe time of transplant, 59.5% were not in complete remission.
KPS score was  80% in all patients and  90% in 33 (89.2%).
One patient expired 19 days post-HCT and two suffered
a relapse 55 and 107 days post-HCT, respectively. Each of
these three patients had HCT-CI scores 3. Utilizing HCT-CI
criteria, 23 (62.1%) had decreased pulmonary function, 6
(16.2%) had decreased cardiovascular function, 3 (8.1%) had
solid tumor history, and 3 (8.1%) had depression or anxiety.
Using an HCT-CI score of 3, 18 patients scoring  3
developed 44 grade 3-5 toxicities, while 19 patients with
a score < 3 developed 20 grade 3-5 toxicities (p ¼ .002).
ANCOVA multivariate analysis demonstrated that an HCT-CI
score of 3 can predict the number of grade 3-5 toxicities (p ¼
.044) independently from age, gender, KPS, diagnoses, and
pre-transplant disease status.
Conclusion: This retrospective study utilizing an HCT-CI
score of 3 predicted grade 3-5 toxicity in the ﬁrst 90 days
following HCT in elderly autologous HCT recipients inde-
pendent of KPS, diagnoses, disease status, age, and gender.
Thepredictive ability of theHCT-CI is superior toperformance
status. AddingHCT-CI to pre-HCTeligibility criteria for elderly
patients should be considered. Use of the HCT-CI may also be
utilized as part of pre-HCT counseling and education.143
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Recent experimental data in murine studies suggests that
hematopoietic stem cells (HSC) may not mobilize as well in
mice with diabetes (DM) compared to non-diabetic mice. We
performed a retrospective study of patients with and
without DM undergoing ﬁrst autologous stem cell mobili-
zation from 1/1/2009 to 1/1/2012 to compare efﬁciency of
mobilization and collection of CD34+ cells. Method of
mobilization was decided by the attending physician.
Chemotherapy and G-CSF were used if therapy or cytor-
eduction was necessary and, per institutional guideline,
cytokine only mobilization was G-CSF 10 ug/kg daily with
apheresis starting on day 5, and plerixafor 0.24 mg/kg was
added on day 4 if the peripheral blood CD34+ cells/ul was
< 15. A total of 343 pts underwent 362 attempts at collection
with 56 (15%) having type II DM. Failure to mobilize CD34
cells was deﬁned as never reaching 10 or greater peripheral
blood CD34+ cells/ul, or collecting less than 2 million CD34+
cells/kg. Both DM and non-DM pts required a median of 2
(range 1-4) days of apheresis for successful collection. The
mean total CD34+ cells/kg x 106 collected (std dev) was 6.12
(2.66) in DM pts vs 6.8 (3.58) in non-DM pts (p¼0.05). When
stratiﬁed by method of mobilization, the mean and median
total CD34+ cells collected were less, and the mean days of
apheresis were more in DM pts, but this did not reach
statistical signiﬁcance. Overall, 11/343 (3.2%) pts failed to
mobilize adequate CD34+cells and did not proceed to
autologous HSC transplant, with 4 of the 11 (36%) having DM.
Engraftment and day 100 transplant outcomes were not
different between pts with and without DM. In conclusion,
pts with DM may mobilize less CD34+ cells, but this appears
to be a small effect that is primarily overcome by current
methods of mobilization, with the majority of patients still
able to proceed to autologous HSC transplant. Larger studies
